Antimicrobial Resistance (AMR) – Investors’ Role in Curbing the Silent Pandemic

Antimicrobial resistance (AMR) is one of the top 10 global public health threats facing humanity according to WHO. Most recent estimates find that 1.27 million deaths were directly attributable to AMR and 4.95 million were associated with AMR in 2019. And this global problem is intensifying.

The misuse and overuse of antibiotics in livestock production is one of the leading causes of increased resistance globally. The topic is highly relevant for agricultural, pharmaceutical and food retail sectors amongst others and the EU recently passed new legislation to address AMR.

On March 30, 2022, Swesif held a webinar to illustrate the risks of AMR but also the opportunities that exist to mitigate it and how investors and corporations are working to address the topic.

Speakers were Teni Ekundare, Head of Investor Outreach at FAIRR, Maria Lundesjö, Project manager ‘Framtidens Mat’ at Axfoundation, Stina Printz, Sustainability strategist at Coop Sverige AB and Jennie Ahrén, Chief Sustainability Officer at Tundra Fonder Emma Henningsson, Active ownership at AP7 and Board member, Swesif moderated.

Previous article3 questions for the new board members
Next articleProject – Sustainable Interest & Credit Management